Get started
Author

Grazia Saturno

Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy
2015 · Bryan W Miller, Jennifer P Morton, et al. · EMBO Molecular Medicine · 299
PDF
Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma
2015 · Maria Romina Girotti, Gabriela Gremel, et al. · Cancer Discovery · 235
Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma
2014 · Maria Romina Girotti, Filipa Lopes, et al. · Cancer Cell · 218
PDF
BRAF Inhibitors Induce Metastasis in RAS Mutant or Inhibitor-Resistant Melanoma Cells by Reactivating MEK and ERK Signaling
2014 · Berta Sanchez-Laorden, Amaya Viros, et al. · Science Signaling · 131
Lysyl oxidase drives tumour progression by trapping EGF receptors at the cell surface
2017 · HaoRan Tang, Leo Leung, et al. · Nature Communications · 93
PDF
Anti-metastatic Inhibitors of Lysyl Oxidase (LOX): Design and Structure–Activity Relationships
2019 · Leo Leung, Dan Niculescu-Duvaz, et al. · Journal of Medicinal Chemistry · 77
Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition
2014 · S. Turajlic, S.J. Furney, et al. · Annals of Oncology · 68
PDF
An in vivo and in vitro comparison of CYP induction in rat liver and intestine using slices and quantitative RT-PCR
2004 · Marcella Martignoni, Ruben de Kanter, et al. · Chemico-Biological Interactions · 64
No longer an untreatable disease: How targeted and immunotherapies have changed the management of melanoma patients
2014 · Maria Romina Girotti, Grazia Saturno, et al. · Molecular Oncology · 49
PDF
Combining TRAIL with PI3 Kinase or HSP90 inhibitors enhances apoptosis in colorectal cancer cells via suppression of survival signaling
2013 · Grazia Saturno, Melanie Valenti, et al. · Oncotarget · 39
PDF
An in vivo and in vitro comparison of CYP gene induction in mice using liver slices and quantitative RT-PCR
2005 · Marcella Martignoni, Ruben de Kanter, et al. · Toxicology in Vitro · 25
Selective modulation of ER-? by estradiol and xenoestrogens in human breast cancer cell lines
2003 · V. Cappelletti, G. Saturno, et al. · Cellular and Molecular Life Sciences · 24
The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers
2020 · G. Saturno, F. Lopes, et al. · Annals of Oncology · 21
PDF
Assessing and managing toxicities induced by kinase inhibitors.
2007 · Raffaella E Castoldi, Giulia Pennella, et al. · PubMed · 17
Expression of Serine/Threonine Protein-Kinases and Related Factors in Normal Monkey and Human Retinas: The Mechanistic Understanding of a CDK2 Inhibitor Induced Retinal Toxicity
2007 · Grazia Saturno, Manuela Pesenti, et al. · Toxicologic Pathology · 16
PDF
Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma
2017 · Maria Romina Girotti, Filipa Lopes, et al. · Cancer Cell · 9
PDF
Abstract LB_A12: Initial results from 2 Phase I studies of NMS-03305293, a selective PARP1 inhibitor
2023 · Marjolein Geurts, Dorothee Gramatzki, et al. · Molecular Cancer Therapeutics · 6
Abstract 1615: NMS-812, a novel potent PERK inhibitor that also inhibits GCN2, exhibits strong anti-tumor activity as single agent and in combination in preclinical models
2023 · Claudia Perrera, Maurizio Pulici, et al. · Cancer Research · 5
Therapeutic efficacy of the paradox-breaking panRAF and SRC drug CCT3833/BAL3833 in KRAS-driven cancer models
2016 · G. Saturno, F. Lopes, et al. · European Journal of Cancer · 5
Discovery and optimization of 4-pyrazolyl-2-aminopyrimidine derivatives as potent spleen tyrosine kinase (SYK) inhibitors
2024 · Giovanni Cervi, Roberto D'Alessio, et al. · European Journal of Medicinal Chemistry · 4
NMS-173, a potent, covalent second generation IDH1/IDH2 inhibitor
2022 · P. Magnaghi, F. Casuscelli, et al. · European Journal of Cancer · 3
Abstract LB-212: Therapeutic efficacy of the paradox-breaking panRAF and SRC drug CCT3833/BAL3833 in KRAS-driven cancer models
2016 · Grazia Saturno, Filipa Lopes, et al. · Cancer Research · 2
Abstract 4167: Ultraviolet radiation cooperates with individual oncogenes to drive melanomagenesis through distinct molecular mechanisms
2016 · Amaya Viros, Malin Pedersen, et al. · Cancer Research · 1
Application of sequencing, liquid biopsies and patient-derived xenografts for personalized medicine in melanoma
2016 · M.R. Girotti, G. Gremel, et al. · European Journal of Cancer · 1
Abstract 3704: Novel panRAF inhibitors active in melanomas that are resistant to BRAF-selective, or BRAF-selective/MEK inhibitor combinations
2014 · Maria R. Girotti, Filipa Lopes, et al. · Cancer Research · 1
Works count: 49
Citation count: 1,413
H-index: 15
I10-index: 15
Year
Topic
Type